NASDAQ:SCYX SCYNEXIS (SCYX) Stock Price, News & Analysis $1.87 -0.07 (-3.61%) (As of 07/5/2024 08:53 PM ET) Add Compare Share Share Today's Range$1.80▼$1.9650-Day Range$1.69▼$2.7752-Week Range$1.35▼$3.87Volume153,300 shsAverage Volume218,470 shsMarket Capitalization$70.65 millionP/E Ratio0.92Dividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get SCYNEXIS alerts: Email Address SCYNEXIS MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside702.1% Upside$15.00 Price TargetShort InterestHealthy2.73% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.01) to ($0.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.08 out of 5 starsMedical Sector316th out of 879 stocksPharmaceutical Preparations Industry144th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingSCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSCYNEXIS has received no research coverage in the past 90 days.Read more about SCYNEXIS's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.73% of the outstanding shares of SCYNEXIS have been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in SCYNEXIS has recently decreased by 6.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SCYX. Previous Next 2.2 News and Social Media Coverage News SentimentSCYNEXIS has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for SCYNEXIS this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for SCYX on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.85% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about SCYNEXIS's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for SCYNEXIS are expected to decrease in the coming year, from ($0.01) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SCYNEXIS is 0.92, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.10.Price to Earnings Ratio vs. SectorThe P/E ratio of SCYNEXIS is 0.92, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.85.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about SCYNEXIS's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).Get the full story here while you can. About SCYNEXIS Stock (NASDAQ:SCYX)SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Read More SCYX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCYX Stock News HeadlinesJuly 1, 2024 | investorplace.com7 Undervalued Biotech Stocks to Buy for Big-Time ReturnsMay 31, 2024 | investorplace.comHidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025July 8, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.May 23, 2024 | investorplace.com3 Stocks Under $10 With Mammoth Growth ProspectsMay 10, 2024 | markets.businessinsider.comBuy Recommendation: Scynexis’s Ibrexafungerp Promises Market Breakthrough and Financial GrowthMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Scynexis on Robust Financials and Promising Antifungal PipelineMay 9, 2024 | investorplace.comSCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | markets.businessinsider.comSCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate UpdateJuly 8, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.May 8, 2024 | finance.yahoo.comInvestors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five yearsApril 30, 2024 | finance.yahoo.comSCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)April 20, 2024 | finance.yahoo.comSCYNEXIS, Inc. (SCYX)April 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for SCYNEXIS on Strong Financials and Promising Pipeline ProspectsApril 9, 2024 | globenewswire.comSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)March 29, 2024 | msn.comSCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023March 28, 2024 | stockhouse.comSCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | globenewswire.comSCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 21, 2024 | benzinga.comSCYNEXIS Stock (NASDAQ:SCYX) Insider TradesSee More Headlines Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/07/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SCYX CUSIPN/A CIK1178253 Webwww.scynexis.com Phone(201) 884-5485Fax201-884-5490Employees29Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+702.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$2.04 Trailing P/E Ratio0.92 Forward P/E RatioN/A P/E GrowthN/ANet Income$67.04 million Net Margins72.18% Pretax Margin72.65% Return on Equity112.89% Return on Assets68.17% Debt Debt-to-Equity RatioN/A Current Ratio3.72 Quick Ratio3.72 Sales & Book Value Annual Sales$140.14 million Price / Sales0.50 Cash Flow$1.89 per share Price / Cash Flow0.99 Book Value$1.96 per share Price / Book0.95Miscellaneous Outstanding Shares37,780,000Free Float36,703,000Market Cap$70.65 million OptionableOptionable Beta1.51 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. David Gonzalez Angulo M.D. (Age 59)CEO, President & Director Comp: $868.03kMr. Ivor Macleod CPA (Age 63)M.B.A., Chief Financial Officer Comp: $626.9kMr. Scott Sukenick J.D. (Age 46)Chief Legal Officer & Corporate Secretary Comp: $623.7kMs. Daniella GiganteVice President of Human Resources & Information TechnologyKey CompetitorsNabriva TherapeuticsNASDAQ:NBRVEntasis TherapeuticsNASDAQ:ETTXRevance TherapeuticsNASDAQ:RVNCNature's Sunshine ProductsNASDAQ:NATRInozyme PharmaNASDAQ:INZYView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 129,153 shares on 5/10/2024Ownership: 4.467%Acadian Asset Management LLCBought 21,700 shares on 5/10/2024Ownership: 1.115%AMH Equity LtdBought 109,600 shares on 5/7/2024Ownership: 1.747%Empowered Funds LLCBought 6,650 shares on 5/7/2024Ownership: 0.234%Simplicity Wealth LLCBought 20,000 shares on 4/24/2024Ownership: 0.053%View All Institutional Transactions SCYX Stock Analysis - Frequently Asked Questions How have SCYX shares performed this year? SCYNEXIS's stock was trading at $2.23 at the beginning of the year. Since then, SCYX shares have decreased by 16.1% and is now trading at $1.87. View the best growth stocks for 2024 here. How were SCYNEXIS's earnings last quarter? SCYNEXIS, Inc. (NASDAQ:SCYX) announced its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.03. The firm earned $1.37 million during the quarter. SCYNEXIS had a net margin of 72.18% and a trailing twelve-month return on equity of 112.89%. When did SCYNEXIS's stock split? SCYNEXIS shares reverse split before market open on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), KushCo (KSHB), Zosano Pharma (ZSAN) and Bionano Genomics (BNGO). This page (NASDAQ:SCYX) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
